Apothecary Pharma has pulled 22 vials of compounded tirzepatide from circulation nationwide after failing to guarantee the products were sterile.
The North Carolina-based pharmaceutical company issued the voluntary recall for prescription tirzepatide injections supplied in 4 mL multidose vials at a concentration of 18 mg/mL, carrying National Drug Code 85091-001-18. The FDA classified the recall as Class II, indicating a situation where use of the product may cause temporary or medically reversible adverse health consequences.
The recall follows a December 2025 FDA warning letter that identified problems putting patients at risk, though regulators have not established a direct connection between those earlier findings and the current recall. The agency regularly publishes such notices to alert healthcare professionals and consumers to potential safety issues involving medications.
Sterility is particularly critical for injectable medications because contaminated products can introduce harmful microorganisms directly into the body, potentially leading to serious infections or other complications. Anyone who received an affected injection and experiences fever, redness, swelling, or worsening pain has been advised to seek medical advice.
Apothecary Pharma has already notified recipients of the recalled product by letter, according to the company. Those who believe they may have received medication included in the recall should check relevant product details and contact a healthcare professional for guidance on next steps.
Tirzepatide has surged in popularity in recent years for its weight-loss benefits, though it was originally developed to treat type 2 diabetes. The drug is currently sold under brand names including Mounjaro and Zepbound. However, the recalled vials are specifically associated with Apothecary Pharma’s compounded version, not the brand-name products.
Health experts explain that the drug works by mimicking hormones involved in regulating appetite and blood sugar levels, helping people feel fuller for longer and reducing hunger. Weight loss is generally gradual rather than immediate, with results building over several months as treatment continues. People using tirzepatide for weight management may begin to notice changes within the first few weeks of treatment, although the amount of weight lost and how quickly results appear can vary significantly from person to person.
The growing demand for tirzepatide has highlighted the importance of medication safety as more patients seek access to the drug for weight management. Compounded versions have emerged as alternatives amid supply constraints and cost considerations for the brand-name products.
No adverse events have been reported in connection with the recalled vials, according to authorities. The recall remains voluntary and limited to the specific lot of compounded product from Apothecary Pharma.
Patients using tirzepatide should verify whether their medication matches the recalled product details, including the NDC number and vial specifications, before taking further action.